The dementia drug is supplied by Janssen Pharmaceutical under an agreement signed between the companies.
As per the terms of the agreement, Reminyl will be marketed by Takeda Pharma with the same brand name in Japan.
Reminyl will be orally administered twice daily, available in three forms of dosage: tablet, orally-disintegrating tablet, and oral solution, allowing patients and caregivers to select an optimal form according to their needs and lifestyles.
Takeda Pharma Marketing Division director and senior vice president Yasuhiko Yamanaka said they launch Reminyl, a new treatment option for Alzheimer-type dementia, for Japanese patients in collaboration with Janssen Pharma.
"We hope that better lives will be achieved by patients and their families, who have been waiting for this medicine for a long time," Yamanaka said.